Navigation Links
Genomic Health Presents Multiple International Studies Demonstrating Worldwide Value of Oncotype DX® Breast Cancer Test
Date:3/17/2011

Test*

The Oncotype DX breast cancer test is a multigene expression test that examines a breast cancer patient's tumor tissue at a molecular level, and gives information about their individual disease to help optimize treatment options. Oncotype DX is the only test incorporated in published ASCO® and NCCN® breast cancer treatment guidelines to predict the likelihood of chemotherapy benefit as well as recurrence for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive.

Additionally, physicians use Oncotype DX to make treatment recommendations for certain node-positive breast cancer patients, and the test report also provides quantitative scores for select individual genes.  Oncotype DX has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in the Journal of Clinical Oncology. Both Medicare and private health plans covering over 95 percent of U.S. insured lives provided reimbursement for Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive through contracts, agreements or policy decisions.  For more information about Oncotype DX for breast cancer, please visit www.oncotypedx.com or www.untileverywomanknows.com.

*ASCO® is a registered trademark of the American Society of Clinical Oncology. NCCN® is a registered trademark of the National Comprehensive Cancer Network. ASCO and NCCN do not endorse any product or therapy.

About Genomic Health

Genomic Health, Inc. (NASDAQ: '/>"/>

SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Reminder Webcast Alert: Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
2. Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
3. Everist Genomics Laboratory Receives Approval From U.S. Regulatory Authorities For High Complexity Clinical Testing
4. Researchers use genomics to investigate TB outbreak
5. Transgenomic to Present at the Lippert/Heilshorn Life Sciences & Medtech Virtual Conference on February 17
6. Genomic Health Announces Results from Biomarker Discovery Program Utilizing Next-Generation Sequencing to Compare Normal and Tumor Breast Tissue
7. Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database
8. Four Community Hospitals Join DNA Directs Genomic Medicine Network
9. Genomic Health Announces Multiple Colon Cancer Studies at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium
10. Everist Genomics Announces External Validation of OncoDefender™-CRC Test for Predicting Recurrence Risk for Stage I and II Colorectal Cancer Patients
11. BioInformatics, LLC New Market Report - Genomics Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... DIEGO and TORONTO , ... TSX: APS), a clinical-stage company developing new therapeutics and ... today announced that William G. Rice , Ph.D., ... the upcoming 27th Annual ROTH Conference on Tuesday, March ... The Ritz Carlton, Laguna Niguel, CA. ...
(Date:3/5/2015)... -- In response to the incorrect assertions by LD, distributed ... on February 12, 2015. Impeto Medical SAS and its ... their SUDOSCAN® devices have been proven to provide accurate ... have the courts decide this dispute rather than the ... written by Key Opinion Leaders, published by significant peer-reviewed ...
(Date:3/5/2015)... March 05, 2015 RMI ... and chronic orthopedic conditions such as meniscal tears, ... elbow, and joint pain due to degenerative conditions ... during orthopedic surgeries to promote better post-surgical outcomes. ... in nearly pain-free bone marrow harvesting with two ...
(Date:3/4/2015)... BALTIMORE , March 4, 2015 The ... of its 2015 Fellows in the Emerging Leaders in ... fostering future leaders in the field of biosecurity, UPMC ... biosecurity from a wide array of backgrounds, including biological ... private sector. "With the vision and ...
Breaking Biology Technology:Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3
... N.C., May 5 ASG, Inc., saw continued ... of neighboring Ockham Development Group. The February merger ... expand the breadth and value of services that ... outsourcing and staffing services or the opportunity to ...
... May 5 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc. ("Neptune") ... its product portfolio., Worldwide Sales and Distribution ... marketing team through the hiring of two, ... recognized backgrounds in the nutraceutical ...
... Uveitis, or inflammation within the eye, is a ... loss roughly comparable to that caused by diabetes. ... program in uveitis, the LUMINATE trials sponsored by ... voclosporin oral capsule) to significantly improve this chronic ...
Cached Biology Technology:CRO Acquisition Seen Boosting Activity, Positioning ASG, Inc., for New Growth in Q2 2Neptune Product and Distribution Update 2Neptune Product and Distribution Update 3Neptune Product and Distribution Update 4First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease 2First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease 3First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease 4
(Date:2/24/2015)... 24, 2015 This report analyzes the worldwide markets for ... Face Biometrics, and Voice Biometrics. The report provides separate comprehensive analytics ... , Europe , Asia-Pacific ... , and Latin America . Annual estimates ... a seven-year historic analysis is provided for these markets. Market data ...
(Date:2/13/2015)... , Feb. 13, 2015 ACT Genomics ... that aims to transform cancer genomic information into ... the company has raised US$ 8 million in the ... in Taipei, Taiwan , ACT ... ACTOnco™. With the aim to implement next generation ...
(Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... have attracted the attention of ornithologists for a long time, ... they use to dispatch their prey. In the book, the ... much of which has accumulated in the ornithological literature and ... within the framework of an integral system of adaptation, are ...
... solutions company Stayhealthy, Inc. announced today that the Honorable ... of Health & Human Services and Governor of Wisconsin, ...  This move is an important step forward in the ... health improvement solutions in clinical, community and corporate wellness ...
... A new discovery in mice by researchers at Wake ... spare some patients with acute myeloid leukemia (AML) from toxic ... AML, the most common form of acute leukemia ... primarily affects the elderly. Despite years of research, outcomes for ...
Cached Biology News:Former HHS Secretary Tommy G. Thompson to Chair Stayhealthy Board 2Former HHS Secretary Tommy G. Thompson to Chair Stayhealthy Board 3Study reveals need for personalized approach in treatment of AML 2Study reveals need for personalized approach in treatment of AML 3
Rabbit polyclonal to 13,14 dihydro 15 keto Prostaglandin E2 ( Abpromise for all tested applications)....
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Arginine vasopressin receptor (AVP-V2), rat. The peptide used for immunization has no significant similarity with AVP V1a or V1b receptors....
Yersinia pestis...
Biology Products: